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Abstract
Background: Analysis of cell free fetal (cff) DNA in maternal plasma is used routinely for non invasive prenatal diagnosis
(NIPD) of fetal sex determination, fetal rhesus D status and some single gene disorders. True positive results rely on
detection of the fetal target being analysed. No amplification of the target may be interpreted either as a true negative
result or a false negative result due to the absence or very low levels of cffDNA. The hypermethylated RASSF1A promoter has
been reported as a universal fetal marker to confirm the presence of cffDNA. Using methylation-sensitive restriction
enzymes hypomethylated maternal sequences are digested leaving hypermethylated fetal sequences detectable. Complete
digestion of maternal sequences is required to eliminate false positive results.
Methods: cfDNA was extracted from maternal plasma (n = 90) and digested with methylation-sensitive and insensitive
restriction enzymes. Analysis of RASSF1A, SRY and DYS14 was performed by real-time PCR.
Results: Hypermethylated RASSF1A was amplified for 79 samples (88%) indicating the presence of cffDNA. SRY real time PCR
results and fetal sex at delivery were 100% accurate. Eleven samples (12%) had no detectable hypermethylated RASSF1A and
10 of these (91%) had gestational ages less than 7 weeks 2 days. Six of these samples were male at delivery, five had
inconclusive results for SRY analysis and one sample had no amplifiable SRY.
Conclusion: Use of this assay for the detection of hypermethylated RASSF1A as a universal fetal marker has the potential to
improve the diagnostic reliability of NIPD for fetal sex determination and single gene disorders.
Citation: White HE, Dent CL, Hall VJ, Crolla JA, Chitty LS (2012) Evaluation of a Novel Assay for Detection of the Fetal Marker RASSF1A: Facilitating Improved
Diagnostic Reliability of Noninvasive Prenatal Diagnosis. PLoS ONE 7(9): e45073. doi:10.1371/journal.pone.0045073
Editor: Cees Oudejans, VU University Medical Center, Netherlands
Received May 4, 2012; Accepted August 13, 2012; Published September 14, 2012
Copyright:  2012 White et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This article presents independent research commissioned by the National Institutes for Health Research (NIHR) under the Programme Grants for
Applied Research programme (the ‘‘RAPID’’ project, RP-PG-0707-10107). LSC receives some funding from the NIHR Biomedical Research Centre at University
College London Hospitals and the Great Ormond Street Hospital Children’s Charity. The views expressed in this publication are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hew@soton.ac.uk
Introduction
Traditionally prenatal diagnosis of fetal genetic status has
depended on the use of invasive diagnostic tests, either amnio-
centesis or chorionic villus sampling (CVS), which carry a small
but significant risk of miscarriage [1] and cannot be performed
until 11 weeks of gestation. However the identification of cell free
fetal (cff) DNA in maternal plasma [2] has offered an alternative
non invasive source of fetal genetic material for prenatal diagnosis.
cffDNA originates from the apoptotic syncytial trophoblasts of the
placenta [3], can be detected from 5 weeks gestation [4] and is
cleared rapidly from the maternal circulation following delivery
[5].
Analysis of cffDNA in maternal plasma is now in routine clinical
diagnostic use for non invasive prenatal diagnosis (NIPD) where
the target fetal sequence is derived from the father or where the
allele arises de novo. NIPD for fetal sex determination can be
carried out at an early gestational age for pregnancies known to be
at risk of a sex-linked genetic condition [6], where a male fetus
would be at risk of inheriting the condition, or conditions such as
congenital adrenal hyperplasia where early treatment with
dexamethasone can reduce the virilisation of female fetuses [7].
NIPD is used for fetal Rhesus D genotyping in D-negative mothers
[8] and for some single gene disorders such as achondroplasia and
beta-thalassemia [9,10,11].
Currently, clinical applications of NIPD require the detection of
the paternally inherited (or de novo) allele to make a definitive
diagnosis. Absence of detection of the paternal target sequence is
either indicative of a true negative result or could also be due the
lack of amplification of the sequence due to low concentrations of
circulating cffDNA or the complete absence of cffDNA in the
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sample. Amplification of a fetal specific marker that confirms the
presence of cffDNA allows a negative result to be more accurately
interpreted as either a true or false negative result. The use of
several fetal identifiers has been reported including the hyper-
methylated RASSF1A promoter [12], Y chromosome sequences for
male pregnancies and panels of common polymorphic short
tandem repeats, SNPs or indel markers [13,14,15,16].
RASSF1A has been demonstrated to be hypermethylated in the
placenta and hypomethylated in the maternal blood [12,17].
Therefore, using methylation-sensitive restriction enzymes hypo-
methylated maternal sequences can be digested leaving only
hypermethylated fetal sequences available for amplification by real
time PCR. However, to eliminate the possibility of generating false
positive results it is important to ensure the complete digestion of
maternal hypomethylated sequences. Using previously published
protocols we have detected up to 34% incomplete digestion of
hypomethylated RASSF1A in clinical samples. Here we present
a modified and simple real time PCR protocol that is applicable
for the detection of hypermethylated RASSF1A promoter
sequences in all pregnancies and demonstrate its clinical utility
for fetal sex determination using SRY and DYS14 real time PCR
analysis.
Materials and Methods
Patient Samples
Informed consent for venepuncture was obtained from ninety
pregnant women attending routine appointments with a commu-
nity midwife (n = 62), at the early pregnancy unit (n = 4), at
a routine ultrasound scan (n = 16) or for an invasive test procedure
(n = 8) at Salisbury NHS Foundation Trust. The study was
approved by the South West 1 Research Ethics Committee A (ref
09/H0104/59). Gestational age at blood collection was confirmed
by routine ultrasound in all cases.
Blood Collection and DNA Extraction
Maternal blood was collected into two 10 ml EDTA tubes and
centrifuged at 1600 g for 10 minutes and the plasma fraction
transferred to a 2 ml centrifuge tube and re-centrifuged at
20,000 g for 10 minutes. The cell free plasma fraction was stored
at 280uC. Cell free DNA was extracted from 3 ml plasma using
the Circulating Nucleic Acid Kit (Qiagen) following the manu-
facturer’s instructions and resuspended in 70 ml AVE buffer.
Restriction Enzyme Digestion Real Time PCR
Restriction digestion reaction and real time PCR conditions
were optimised on a separate training set of 90 plasma samples
obtained from the SAFE-RAPID sample bank at Great Ormond
Street Children’s Hospital prior to commencing this study [18].
Three 40 ml restriction enzyme digestion reactions were prepared
for each sample: undigested control, methylation sensitive di-
gestion and methylation insensitive digestion. Each reaction
contained 20 ml cfDNA, 16Buffer 4 (New England Biolabs) and
no enzyme (undigested control), 2 U TseI and 4 U BsmI
(methylation insensitive digest) and 2 U BstYI and 2 U BstUI
(methylation sensitive digest). Samples were incubated at 60uC
(undigested and methylation sensitive digest) and 65uC (methyl-
ation insensitive digest) for 2 hours. Additional restriction enzymes
were then added to the reaction and the samples digested further
at 37uC for 2 hours using no enzyme (undigested control), 8 U
EcoRI, 8 U MspI and 4 U HaeIII (methylation insensitive digest)
and 8 U EcoRI, 8 U HhaI and 4 U HpaII (methylation sensitive
digest). All enzymes were supplied by New England Biolabs.
cfDNA from male plasma was digested for each batch of samples
analysed and performed as a digest control for the RASSF1A
methylation insensitive and methylation sensitive digests. These
digests should proceed to completion and therefore no RASSF1A
amplification products should be observed following real time
PCR. Further information regarding the selection of the restriction
enzymes and details of the cleavage sites of the enzymes in the
RASSF1A amplicon are given in Figure S3.
Real Time PCR
5 ml of digested cfDNA was added to a 20 ml real time PCR
containing 300 nM of forward and reverse primers for either
RASSF1A or SRY (Table 1), 1X Power SYBR green PCR master
mix (Life Technologies Corporation) and 0.2 U AmpErase Uracil
N-glycosylase (Life Technologies Corporation). Products were
amplified using a Rotorgene 6000 (Qiagen) with the following
cycling conditions; 50uC for 10 minutes, 95uC for 10 minutes, 50
cycles of 95uC for 15 seconds, 60uC for 60 seconds acquiring on
the Green channel. Samples were then melted from 65uC to 99uC
with a 1uC increment at each step acquiring on the green channel.
The threshold was set at 0.06 for all analyses.
Samples that were negative for SRY or had fewer than 9 positive
replicates were also tested for the multicopy marker DYS14
sequence of the TSPY gene on the Y chromosome [19]. 5 ml of
digested DNA was added to a 20 ml real time PCR containing
300 nM of forward and reverse primers and 200 nM of probe
(Table 1) and 1X TaqMan Universal PCR master mix (Life
Technologies Corporation). Products were amplified using a Ro-
torgene 6000 (Qiagen) with the following cycling conditions; 50uC
for 2 minutes, 95uC for 10 minutes, 50 cycles of 95uC for 15
seconds, 60uC for 60 seconds acquiring on the Green channel.
The threshold was set at 0.06 for all analyses. No template controls
and cfDNA extracted from a male plasma sample were included as
negative and positive controls respectively for the SRY, DYS14 and
RASSF1A assays. cfDNA from male plasma acts as positive control
for the amplification of SRY (all replicates), DYS14 (all replicates)
and RASSF1A (three replicates; undigested sample only). The
cfDNA from male plasma also acts as a digest control for the
RASSF1A methylation insensitive and methylation sensitive digests
as digestion should proceed to completion and no RASSF1A
amplification products should be observed.
Data Analysis
Data analysis parameters were optimised on the training set of
90 plasma samples obtained from Great Ormond Street
Children’s Hospital [18]. The presence of RASSF1A was de-
termined by positive real time PCR amplification plots (Ct value
,45) and a correct melt profile showing a specific peak at 91.2uC
Table 1. Sequences of PCR primers and probes for real time
PCR assays.
Primer Name Sequence 59 to 39 Reference
RASSF1A Forward agcctgagctcattgagctg [12]
RASSF1A Reverse accagctgccgtgtgg
SRY Forward tggcgattaagtcaaattcgc [4]
SRY Reverse ccccctagtaccctgacaatgtatt
DYS14 Forward gggccaatgttgtatccttctc [19]
DYS14 Reverse gcccatcggtcacttacacttc
DYS14 Probe FAM-6-tctagtggagaggtgctc–BHQ1
doi:10.1371/journal.pone.0045073.t001
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(Figure S1). Three replicates for each RASSF1A restriction digest
were analysed. The no digest control (analyses total cfDNA)
required 3 replicates to be positive for analysis to be undertaken.
For the methylation insensitive digest (control for complete
enzyme digestion of RASSF1A target sequence) complete digestion
was assumed to have occurred if no replicates were positive. For
the methylation sensitive digest, $2 out of 3 replicates were
required to be positive to confirm the presence of hypermethylated
fetal DNA. Samples with fewer than 2 positive replicates were not
considered to have sufficient cffDNA present for reliable in-
terpretation of the SRY result. Nine SRY (or DYS14) replicates were
analysed for each patient sample (three from each digest) and the
sample was considered to be male if 6 or more replicates showed
amplification (Ct value ,45) and a correct melt profile showing
a specific peak at 80.5uC (Figure S1). Figure 1 shows the
theoretical results for a male and female fetus, a case with no
cffDNA, and a case with no cfDNA. All samples in this study were
analysed in a blinded fashion.
Results
Sample Cohort Composition and Blood Transit Time
Fetal sex at delivery and pregnancy outcome were recorded for
all samples. There were 37 female, 52 male and one case of female
twins. Maternal ages ranged from 16–43 years (mean= 30 years)
and gestational ages ranged from 5–23.2 weeks (mean= 9.1
weeks). All blood samples were received in the laboratory within
72 hours of collection.
Real Time PCR Analysis for RASSF1A and SRY
All cases showed positive amplification of RASSF1A in the
undigested sample indicating that total cell free DNA had been
extracted successfully in all cases. Hypermethylated RASSF1A, was
amplified in $2 out of 3 replicates for the methylation sensitive
restriction enzyme digest for 79 samples (88%) indicating the
presence of cffDNA. Of these, 45 showed amplification of SRY ($6
out of 9 replicates positive) and were male at delivery and 33 had
no detectable SRY (0 out of 9 replicates positive) and were female
at delivery (including the XX twins). One sample was male at
delivery but only showed amplification of SRY in only 3 out of 9
replicates and therefore this result would have been classified as
inconclusive despite the detection of sufficient cffDNA. Hyper-
methylated RASSF1A was amplified in ,2 replicates in 11 cases
and these would have failed the data analysis parameters for
reporting a clinical result. Of these, 10 samples had gestational
ages less than 7 weeks 2 days which could explain the low level or
absence of cffDNA in the samples [4]. Of the male samples (n = 6),
four had fewer than 3 replicates positive for SRY (i.e. an
inconclusive result) and two samples had 6 replicates positive for
SRY. One male sample showed 0 replicates positive for both
hypermethylated RASSF1A and SRY and therefore could have
been mis-reported as female if the RASSF1A assay had not been
used. All samples showed complete enzyme digestion of RASSF1A
in the methylation insensitive digest reactions (see Figure S1 for
examples).
Real Time PCR Analysis of DYS14 [19]
Samples that had fewer than 9/9 replicates positive for SRY
were also tested for the multicopy marker sequence DYS14 present
in the TSPY gene on the Y chromosome (n= 61; 24 male, 37
female). Eleven female samples showed 0/9 replicates positive for
DYS14 but the remainder (n = 26) showed $1 replicate positive
(range 1–8, mean 2.4) with an average Ct value of 39.2 (SD 1.7).
The male samples (n = 24) had 9/9 DYS14 replicates positive with
an average Ct value of 32.5 (SD 1.8). The male sample that had no
amplification of hypermethylated RASSF1A or SRY showed 9/9
replicates positive for DYS14 however the mean Ct value was 38.2.
Figure 2 shows box plots of the Ct values for RASSF1A, SRY and
DYS14 for male and female pregnancies.
Figure 1. Schematic representation of the possible results obtained using hypermethylated RASSF1A as a universal fetal marker
when determining fetal sex by NIPD for a male fetus, female fetus, a case where no cell free fetal DNA is present and a case where
no total cell free DNA is present. Ticks represent the presence of amplified products from either the SRY assay or the RASSF1A assay. Crosses
represent no amplification of SRY or RASSF1A amplicons.
doi:10.1371/journal.pone.0045073.g001
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Discussion
Detection of hypermethylated RASSF1A promoter sequences
can be used to confirm the presence of cffDNA in diagnostic
samples. The RASSF1A promoter sequence is very GC rich and is
therefore problematic to fully digest and amplify by real time
PCR. We have made several modifications to previously published
protocols [12,20] to enhance the complete digestion of hypo-
methylated RASSF1A sequences, monitor that the digestion of the
target has gone to completion and also improve the efficiency and
interpretation of RASSF1A real time PCR. In preliminary
experiments using published protocols we observed that in-
complete digestion of RASSF1A was common in plasma samples
derived from men and non-pregnant women where RASSF1A
should not be observed following digestion with methylation
sensitive enzymes (Figure S2a) and 25/73 (34%) of the samples
from the initial training set where the Ct values of the BstU1 only
digested DNA [12] were lower than those digested with optimised
digestion protocols (Figure S2b). Using our training set we
undertook significant optimisation of the restriction enzyme
digestion protocol with the addition of enzymes that cut outside
the target amplicon to reduce genome complexity (Figure S3).
This resulted in an improved protocol where the amplicon was
shown to have been fully digested. Also, the low of efficiency of the
hydrolysis probe assay (0.86, standard curve gradient 23.7) made
interpretation of results difficult at high Ct values (low fetal DNA)
as the amplification curves were not easily interpreted as being
positive or negative. Therefore, we altered the real time PCR
protocol to use SYBR Green rather than a hydrolysis probes as
this resulted in improvements in the amplification efficiency to
0.98 (standard curve gradient 23.38). Use of a SYBR Green assay
also enabled improvement in the interpretation of low level
amplification signals by using melt curve analysis at the end of the
real time PCR run. Inclusion of melt curve analysis allowed
unambiguous interpretation of any non-specific amplification
events that can occur when there are only low amounts of
template DNA present. Only amplification events that resulted in
a melt peak at 80.5uC or 91.2uC were scored as positive replicates
for SRY and RASSF1A respectively (Figure S1). Although it may be
desirable to multiplex the fetal target sequence and RASSF1A,
using two differentially labelled hydrolysis probes, having a single
SYBR Green RASSF1A assay means that this can be used in an
economic manner in conjunction with other single gene tests e.g.
rhesus D testing, achondroplasia without the need for extensive re-
optimisation and validation of PCR multiplexes in a diagnostic
setting.
Using the modified protocol we assessed the utility of the assay
for confirmation of cffDNA when undertaking NIPD for fetal sex
determination. Hypermethylated RASSF1A was amplified for 79
samples (88%) indicating the presence of cffDNA. For these
samples the SRY real time PCR results and fetal sex at delivery
were 100% concordant indicating that the test is 96–100%
accurate with a 95% confidence interval [21]. As expected,
insufficient levels of cffDNA (hypermethylated RASSF1A) were
observed in most (n = 10) samples that had a gestational age of 7
weeks or less. This is concordant with a recently published study of
a clinical audit of fetal sex determination that showed that
discordant results could be obtained if testing is performed before
7 weeks [6]. Therefore, it is advisable that an accurate dating scan
is performed prior to testing to ensure that the gestational age is
.7 weeks. However, levels of cffDNA vary in pregnant women
and the use of the RASSF1A assay should be considered for all
samples to ensure that sufficient cffDNA is present to enable
confident interpretation of a test result. For example, in this study
two samples of gestational age ,7 weeks had reportable levels of
hypermethylated DNA and 7 replicates positive for SRY analysis
and were phenotypically male at birth. Conversely a sample of
gestational age 10 weeks 4 days showed unreportable levels of
hypermethylated RASSF1A and an inconclusive number of positive
SRY replicates. Using digital droplet PCR to quantify fetal load
Figure 2. Box plots showing the Ct values for RASSF1A, SRY and DYS14 real time PCR assays for male and female pregnancies. The
mean Ct values were 33.9 (RASSF1A, male fetuses), 34.2 (RASSF1A, female fetuses), 33.0 (SRY, male fetuses), 0 (SRY, female fetuses), 32.5 (DYS14, male
fetuses) and 39.2 (DYS14, female fetuses).
doi:10.1371/journal.pone.0045073.g002
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(RASSF1A) and fetal sex (SRY) it has been shown that the Pearson’s
correlation coefficient between SRY and RASSF1A fetal loads is
97.3 with the RASSF1A fetal loads measured for some samples
being lower than those determined using SRY [17]. It therefore
appears that fetal DNA may not be completely hypermethylated in
all samples. This may account for the cases which have an
inconclusive SRY result but negative RASSF1A result. In all cases
where unreportable levels of hypermethylated RASSF1A are
obtained we recommend that repeat blood samples should be
requested and testing repeated.
Analysis of samples for fetal sex determination using the multi
copy marker DYS14 has been reported as having a higher
sensitivity of detection [19]. However in this study we observed
that 70% of female samples showed at least 1/9 replicates positive
for DYS14 amplification although the Ct values for these samples
(mean 39.2) were significantly higher than those obtained for male
samples (mean Ct 32.5) (Figure 2). This has also been observed in
an audit of reliability of NIPD for fetal sex determination where
the same DYS14 primer and probe set was used [16]. No
amplification of SRY was observed in the same set of female
samples and therefore, if only one Y chromosome target is used for
analysis, we would recommend the use of SRY for fetal sex
determination as there is less risk of reporting a false positive result.
This modified protocol for detection of fetal specific hyper-
methylated RASSF1A is applicable to all pregnancies since is it
polymorphism independent and can be performed at the same
time as the fetal sex determination on the same aliquot of cffDNA.
The SRY and RASSF1A assays have identical reaction conditions
and can be amplified in the same plate and therefore results can be
reported within 48 hours of receipt of the maternal blood sample.
The assay could also be used for NIPD of single gene disorders and
fetal RhD status provided that the restriction enzymes do not cut
within the target amplicon. Use of this assay for the detection of
hypermethylated RASSF1A as a universal fetal marker has the
potential to improve the diagnostic reliability of NIPD for fetal sex
determination and single gene disorders.
Supporting Information
Figure S1 Examples of PCR amplification plots and melting
profiles for the SRY and RASSF1A real time SYBR green PCR
assays.
(PDF)
Figure S2 (a) Amplification plots showing the difference in
efficiency of three methylation sensitive RASSF1A restriction
enzyme digest protocols using cell free DNA extracted from the
plasma of a non-pregnant female. (b) Amplification plots showing
an example of the difference in efficiency of two methylation
sensitive RASSF1A restriction enzyme digest protocols using cell
free DNA extracted from the same plasma sample from a pregnant
female.
(PDF)
Figure S3 Details of restriction enzyme digests.
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